Get the Stockscreener App
1.17
5.65%
-0.07
After Hours:
1.15
-0.02
-1.71%
Decoy Therapeutics Inc stock is traded at $1.17, with a volume of 88,905.
It is down -5.65% in the last 24 hours and down -56.83% over the past month.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
See More
Previous Close:
$1.24
Open:
$1.27
24h Volume:
88,905
Relative Volume:
0.72
Market Cap:
$766.57K
Revenue:
Net Income/Loss:
$-13.03M
P/E Ratio:
-0.00943
EPS:
-124.0371
Net Cash Flow:
$-6.53M
1W Performance:
-27.33%
1M Performance:
-56.83%
6M Performance:
-81.13%
1Y Performance:
+0.00%
1-Day Range:
$1.15
$1.27
1-Week Range:
$1.15
$1.52
52-Week Range:
$1.15
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Name
Decoy Therapeutics Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
1.17 | 766.57K | 0 | -13.03M | -6.53M | -124.04 |
VRTX
Vertex Pharmaceuticals Inc
|
498.50 | 126.35B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
226.30 | 90.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
778.36 | 80.14B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.30 | 51.46B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.52 | 41.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-26 | Initiated | Ladenburg Thalmann | Buy |
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Stock (DCOY) Latest News
Form S-1 Decoy Therapeutics Inc For: 8 October By Investing.com - Investing.com Canada
Decoy Therapeutics Inc (DCOY) Stockholders Plan to Sell 2.37M Sh - GuruFocus
About 10 public companies will meet investors in New York, including Decoy Therapeutics. - Stock Titan
Decoy Therapeutics Completes Warrant Inducement, Raises $3.85 Million in Gross Proceeds - Kalkine Media
Form 8K Decoy Therapeutics Inc For: 23 September By Investing.com - Investing.com Canada
Form 8K Decoy Therapeutics Inc For: 23 September By Investing.com - Investing.com India
Form 8K Decoy Therapeutics Inc For: 23 September By Investing.com - Investing.com UK
A cut from $5.91 to $3.25 brought Decoy Therapeutics (DCOY) cash, plus new rights to buy shares. - Stock Titan
DCOY Stock Volatility Spikes As Traders Track Key Levels - stockstotrade.com
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket - Benzinga
New stock-buying rights can be used immediately, Decoy says, rather than after a shareholder vote - Stock Titan
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release - PR Newswire
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release - cherokeephoenix.org
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules - TradingView
An investor is set to pay Decoy Therapeutics $3.85 million for shares - Stock Titan
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules - PR Newswire
Curvature Securities LLC is acting as the sole placement agent in connection with this warrant inducement transaction. - nasdaq.com
DCOY Stock Slides As Cash-Rich Biotech Tests Key Support - timothysykes.com
Decoy Therapeutics shareholders approve warrant issuance and share reduction - Investing.com
Form 8K Decoy Therapeutics Inc For: 15 September By Investing.com - Investing.com Australia
Form 8K Decoy Therapeutics Inc For: 15 September By Investing.com - Investing.com India
Form 8K Decoy Therapeutics Inc For: 15 September By Investing.com - Investing.com UK
Investors approve new warrants, shrink share pool at Decoy Therapeutics (NASDAQ: DCOY) - Stock Titan
Decoy Therapeutics CEO to present antiviral dru... - Pluang
Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - TMX Newsfile
Decoy Therapeutics Grants 3,900 Shares to Chief Business Officer Marschel Peter Klaus - kalkinemedia.com
Decoy Therapeutics Grants 2,000 Shares to Insider Gauthier Patricia G. at No Cost on August 31, 2026 - kalkinemedia.com
Director at Decoy Therapeutics (DCOY) awarded 2,000 restricted shares vesting in 2027 - Stock Titan
Decoy Therapeutics (DCOY) awards CEO 33,455 restricted shares - Stock Titan
Decoy Therapeutics (DCOY) awards CBO stock at $0 per share - Stock Titan
Decoy Therapeutics (DCOY) CFO granted multi-year stock award - Stock Titan
Chief scientist at Decoy Therapeutics (DCOY) gets 4,216-share stock grant - Stock Titan
Decoy Therapeutics (DCOY) director gets 3,000-share stock grant - Stock Titan
Director at Decoy Therapeutics (DCOY) granted 2,000 shares vesting in 2027 - Stock Titan
Director at Decoy Therapeutics (DCOY) gets 2,000-share grant vesting in 2027 - Stock Titan
Decoy Therapeutics (DCOY) awards 3,000 $0.00 shares to director - Stock Titan
Director at Decoy Therapeutics (DCOY) granted 2,000 restricted shares - Stock Titan
Moody Capital Solutions - TMX Newsfile
Decoy (DCOY) Results Check: EPS Prints Above Forecast in the Current Update; Post-Earnings: The Stock Records a 2.81% DecreaseRevenue Guidance Range - vinanet.vn
ARMISTICE CAPITAL, LLC Acquires Shares of Decoy Therapeutics Inc (DCOY) - GuruFocus
Decoy (DCOY) Latest Quarter: The Available Earnings Metric Delivers a Beat on the Day; After Earnings: Shares Rise 0.29% in the Latest SessionRevenue Guidance Range - vinanet.vn
Decoy (DCOY) Trading Levels Update: Adds 1.14% to Close at $3.56 for the Current Session; Chart Reference - vinanet.vn
DCOY Q3 2024 Earnings: Narrower Loss of -136.8 per Share Delivers Positive SurpriseCash Flow Report - vinanet.vn
Decoy Therapeutics (DCOY) Advances 1.42% to $3.58, Holding Above SupportCTA Positioning - vinanet.vn
Armistice Capital (DCOY) discloses 65,503-share, 9.99% holding in Decoy Therapeutics - Stock Titan
Decoy Therapeutics (DCOY) Advances 1.42% to $3.58, Holding Above SupportIV Crush Alert - dars.gov.et
DCOY Q2'26 Earnings: EPS estimate is (2.88) USD - TradingView
Decoy Therapeutics: Q2 Earnings Snapshot - Barchart.com
Decoy Therapeutics: Q2 Earnings Snapshot | Associated Press | syndication news - Enidnews.com
Decoy Therapeutics: Q2 Earnings Snapshot - KING5.com
Decoy Therapeutics Inc Stock (DCOY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Decoy Therapeutics Inc Stock (DCOY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HANISH ARNOLD C | Director |
Dec 30 '25 |
Sale |
0.64 |
12 |
8 |
0 |
| HANISH ARNOLD C | Director |
Nov 20 '25 |
Buy |
0.75 |
5,000 |
3,740 |
5,015 |
| Rosenblum Mark J | Exec VP Finance, CFO |
Nov 20 '25 |
Buy |
0.80 |
20,000 |
16,000 |
20,177 |
6.10%
5.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):